Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism
Article first published online: 26 JUN 2009
© 2009 The Authors. Journal compilation © 2009 The British Pharmacological Society
British Journal of Clinical Pharmacology
Volume 68, Issue 4, pages 634–637, October 2009
How to Cite
Nakhjavani, M., Hamidi, S., Esteghamati, A., Abbasi, M., Nosratian-Jahromi, S. and Pasalar, P. (2009), Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. British Journal of Clinical Pharmacology, 68: 634–637. doi: 10.1111/j.1365-2125.2009.03483.x
- Issue published online: 15 OCT 2009
- Article first published online: 26 JUN 2009
- Received 15 December 2008Accepted 18 June 2009
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Spironolactone is known to have antiandrogenic features and agonist activity at progesterone receptors, which are responsible for several of its hormonal side-effects.
• The potential unfavourable influences of this medication on serum lipoproteins have long been a concern but literature lacks sufficient data on this issue.
WHAT THIS STUDY ADDS
• Spironolactone can adversely affect serum lipids by decreasing high-density lipoprotein and increasing low-density lipoprotein in women treated for hirsutism on a short-term basis.
To investigate the effects of spironolactone on serum lipids in women with hirsutism over a 3-month period.
In a prospective setting, 27 hirsute women (20 with polycystic ovary syndrome and seven with idiopathic hirsutism) with a mean age of 23.0 ± 5.1 years were studied at baseline and 3 months after receiving a daily dose of 100 mg of spironolactone. Patients did not receive any other medications and did not go through a specific diet during the study. Lipid profile, fasting blood glucose, testosterone, dehydroepiandrosterone sulphate (DHEAS) and prolactin (PRL) were measured at baseline and 3 months after therapy.
Mean body mass index of patients was 26.1 ± 5.1 kg m−2 before treatment and 25.9 ± 5.7 kg m−2 after treatment (NS). The therapy was associated with a significant decline of mean high-density lipoprotein (HDL), 39.5 mg dl−1[95% confidence interval (CI) 35.6, 43.4]vs. 32.2 mg dl−1 (95% CI 29.2, 35.2), and a significant increase in mean low-density lipoprotein (LDL), 133.1 mg dl−1 (95% CI 120.2, 146) vs. 150.8 mg dl−1 (95% CI 139.1, 162.5), and cholesterol/HDL ratio, 5 (95% CI 4.4, 5.6) vs. 6.4 (95% CI 5.7, 7.1) (P < 0.05). No significant change was noted in total cholesterol, triglyceride or fasting blood glucose levels. Serum values of testosterone, DHEAS and PRL decreased significantly after 3 months of therapy (P < 0.05).
Spironolactone might have adverse effects on serum lipoprotein levels by increasing LDL and decreasing HDL over a short course of treatment. While treating hirsutism with spironolactone, special care should be given to women with metabolic disorders such as dyslipidaemia.